RxDoctor Payments Data

Samuel Markind

Neurology · Danbury, CTNPI 1427053404

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $1,750 of the $2,210 with a category attached, or 79.2%. Eli Lilly accounts for 79.2% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2021 at $1,750 and has fallen 94.9% since, to $89 in 2022.

$2,210in general payments, 2019–2025

Across 23 payments — averaging $96.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$2K
  • Lilly USA, LLC$89
  • Novartis$62
  • Biogen$52
  • Sunovion Pharmaceuticals Inc.$41
  • CSL Behring$29
  • plus $188 from 10 others
$232,550in research payments, 2019–2025

Across 30 payments — averaging $7751.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$174K
  • Genentech, Inc.$58K

What the payments were for

  • Consulting fees$1,75079%
  • Food & beverage$46021%

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,210 in reported general payments places this provider in the 60th percentile of 280 neurology providers in Connecticut.

See all neurology providers in Connecticut →

Other neurology in Danbury

See the full list for Connecticut →

Where these figures come from

Is this you, or does something look wrong? →